{"id":326326,"date":"2026-10-26T11:33:48","date_gmt":"2026-10-26T06:03:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=326326"},"modified":"2026-10-26T11:33:48","modified_gmt":"2026-10-26T06:03:48","slug":"specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/","title":{"rendered":"3 Specialty Pharma Maker, Global Generics Leader and Branded Medicines Company Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories: ROE of 11.1% to 17.1% and FY22 to FY26 revenue CAGR of 9.1% to 14.3%. Prices as of 23 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three branded pharma and specialty generics stocks to watch are JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories. Their return on equity ranges from 11.1% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 14.3%. JB Chemicals and Pharmaceuticals leads on both return on equity at 17.1% and revenue growth at 14.3% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Branded pharma and specialty generics stocks let investors follow companies that serve a growing part of the Indian economy. JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories cover a specialty pharma maker, a global generics leader and a branded medicines company.<\/p>\n<p>This list covers three branded pharma and specialty generics stocks with complete current figures: JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#What_Are_Branded_Pharma_and_Specialty_Generics_Stocks\" title=\"What Are Branded Pharma and Specialty Generics Stocks?\">What Are Branded Pharma and Specialty Generics Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Branded_Pharma_and_Specialty_Generics_Stocks_at_a_Glance\" title=\"Branded Pharma and Specialty Generics Stocks at a Glance\">Branded Pharma and Specialty Generics Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Why_Do_Branded_Pharma_and_Specialty_Generics_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Branded Pharma and Specialty Generics Stocks Have a Strong Roadmap in India?\">Why Do Branded Pharma and Specialty Generics Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Why_JB_Chemicals_and_Pharmaceuticals_Features_Among_These_Branded_Pharma_and_Specialty_Generics_Stocks\" title=\"Why JB Chemicals and Pharmaceuticals Features Among These Branded Pharma and Specialty Generics Stocks\">Why JB Chemicals and Pharmaceuticals Features Among These Branded Pharma and Specialty Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Why_Dr_Reddys_Laboratories_Features_Among_These_Branded_Pharma_and_Specialty_Generics_Stocks\" title=\"Why Dr. Reddy&#8217;s Laboratories Features Among These Branded Pharma and Specialty Generics Stocks\">Why Dr. Reddy&#8217;s Laboratories Features Among These Branded Pharma and Specialty Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Why_Alkem_Laboratories_Features_Among_These_Branded_Pharma_and_Specialty_Generics_Stocks\" title=\"Why Alkem Laboratories Features Among These Branded Pharma and Specialty Generics Stocks\">Why Alkem Laboratories Features Among These Branded Pharma and Specialty Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#JB_Chemicals_and_Pharmaceuticals_vs_Dr_Reddys_Laboratories_vs_Alkem_Laboratories_on_Key_Financials\" title=\"JB Chemicals and Pharmaceuticals vs Dr. Reddy&#8217;s Laboratories vs Alkem Laboratories on Key Financials\">JB Chemicals and Pharmaceuticals vs Dr. Reddy&#8217;s Laboratories vs Alkem Laboratories on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Key_Risks_to_Check_Before_Investing_in_Branded_Pharma_and_Specialty_Generics_Stocks\" title=\"Key Risks to Check Before Investing in Branded Pharma and Specialty Generics Stocks\">Key Risks to Check Before Investing in Branded Pharma and Specialty Generics Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Final_Thoughts_on_Branded_Pharma_and_Specialty_Generics_Stocks\" title=\"Final Thoughts on Branded Pharma and Specialty Generics Stocks\">Final Thoughts on Branded Pharma and Specialty Generics Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#What_are_branded_pharma_and_specialty_generics_stocks\" title=\"What are branded pharma and specialty generics stocks?\">What are branded pharma and specialty generics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Which_branded_pharma_and_specialty_generics_stocks_are_covered_in_this_list\" title=\"Which branded pharma and specialty generics stocks are covered in this list?\">Which branded pharma and specialty generics stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Why_do_branded_pharma_and_specialty_generics_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do branded pharma and specialty generics stocks have a strong future roadmap in India?\">Why do branded pharma and specialty generics stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#How_has_JB_Chemicals_and_Pharmaceuticals_performed_financially\" title=\"How has JB Chemicals and Pharmaceuticals performed financially?\">How has JB Chemicals and Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#How_has_Dr_Reddys_Laboratories_performed_financially\" title=\"How has Dr. Reddy&#8217;s Laboratories performed financially?\">How has Dr. Reddy&#8217;s Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#How_has_Alkem_Laboratories_performed_financially\" title=\"How has Alkem Laboratories performed financially?\">How has Alkem Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#What_risks_should_investors_check_before_buying_branded_pharma_and_specialty_generics_stocks\" title=\"What risks should investors check before buying branded pharma and specialty generics stocks?\">What risks should investors check before buying branded pharma and specialty generics stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/specialty-pharma-maker-global-generics-leader-and-branded-medicines-company-stocks-roadmap-lodestar-list\/#Is_this_list_of_branded_pharma_and_specialty_generics_stocks_investment_advice\" title=\"Is this list of branded pharma and specialty generics stocks investment advice?\">Is this list of branded pharma and specialty generics stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Branded_Pharma_and_Specialty_Generics_Stocks\"><\/span><strong>What Are Branded Pharma and Specialty Generics Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Branded pharma and specialty generics stocks are listed drug makers that sell branded medicines in India and generics abroad. Their earnings depend on new launches, chronic therapy growth, regulatory approvals and pricing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Branded_Pharma_and_Specialty_Generics_Stocks_at_a_Glance\"><\/span><strong>Branded Pharma and Specialty Generics Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/jbchepharm\/jb-chemicals-and-pharmaceuticals-ltd-share-price-today\">JB Chemicals and Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,408.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38,731<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">54.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr. Reddy&#8217;s Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,229.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">103,667<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.20<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/alkem\/alkem-laboratories-ltd-share-price-today\">Alkem Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,947<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59,723<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.15<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories trade at a P\/E below the industry P\/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing branded pharma and specialty generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Branded_Pharma_and_Specialty_Generics_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Branded Pharma and Specialty Generics Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Branded pharma and specialty generics stocks have a strong roadmap in India because rising healthcare access, a growing chronic disease burden and a trusted export base keep lifting demand for medicines.<\/p>\n<ul>\n<li><strong>Chronic therapies.<\/strong> Long-term treatments give repeat demand.<\/li>\n<li><strong>Export generics.<\/strong> Overseas approvals widen markets.<\/li>\n<li><strong>Domestic brands.<\/strong> Doctors prescribe trusted medicines.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_JB_Chemicals_and_Pharmaceuticals_Features_Among_These_Branded_Pharma_and_Specialty_Generics_Stocks\"><\/span><strong>Why JB Chemicals and Pharmaceuticals Features Among These Branded Pharma and Specialty Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the branded pharma and specialty generics stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.<\/p>\n<p>The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P\/E of 54.6, above the industry P\/E of 35.8.<\/p>\n<p>Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.<\/p>\n<p><strong>Roadmap:<\/strong> The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the growth of key domestic brands and the order flow in contract manufacturing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dr_Reddys_Laboratories_Features_Among_These_Branded_Pharma_and_Specialty_Generics_Stocks\"><\/span><strong>Why Dr. Reddy&#8217;s Laboratories Features Among These Branded Pharma and Specialty Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the medicine maker business shares on this list, Dr. Reddy&#8217;s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.<\/p>\n<p>Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.<\/p>\n<p>The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P\/E of 32.6, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.<\/p>\n<p><strong>What to watch:<\/strong> Monitor launches of complex generics and the progress of biosimilar programmes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Alkem_Laboratories_Features_Among_These_Branded_Pharma_and_Specialty_Generics_Stocks\"><\/span><strong>Why Alkem Laboratories Features Among These Branded Pharma and Specialty Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.<\/p>\n<p>In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.<\/p>\n<p>Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P\/E of 27.1, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> Alkem&#8217;s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"JB_Chemicals_and_Pharmaceuticals_vs_Dr_Reddys_Laboratories_vs_Alkem_Laboratories_on_Key_Financials\"><\/span><strong>JB Chemicals and Pharmaceuticals vs Dr. Reddy&#8217;s Laboratories vs Alkem Laboratories on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three branded pharma and specialty generics stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">JB Chemicals and Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,463<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,208<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">709<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dr. Reddy&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22,030<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35,059<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,158<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Alkem Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,797<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,296<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,353<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. Dr. Reddy&#8217;s Laboratories has the largest FY26 revenue at Rs 35,059 crore, and JB Chemicals and Pharmaceuticals shows the fastest revenue growth with a 14.3% compound annual rate. A useful habit with branded pharma and specialty generics stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Branded_Pharma_and_Specialty_Generics_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Branded Pharma and Specialty Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these branded pharma and specialty generics stocks, the main points are:<\/p>\n<ul>\n<li><strong>Regulatory checks.<\/strong> Plant inspections can affect approvals.<\/li>\n<li><strong>Price pressure.<\/strong> Generic prices abroad can fall.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter branded pharma and specialty generics stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Branded_Pharma_and_Specialty_Generics_Stocks\"><\/span><strong>Final Thoughts on Branded Pharma and Specialty Generics Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Branded pharma and specialty generics stocks reward investors who follow demand trends, order books and margins together. JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories each have a clear plan to widen their reach. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Dr. Reddy&#8217;s Laboratories at Rs 1,229.5 and Alkem Laboratories at Rs 4,947.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track branded pharma and specialty generics stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_branded_pharma_and_specialty_generics_stocks\"><\/span><strong>What are branded pharma and specialty generics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Branded pharma and specialty generics stocks are listed drug makers that sell branded medicines in India and generics abroad. Their earnings depend on new launches, chronic therapy growth, regulatory approvals and pricing. This list looks at three of them, JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_branded_pharma_and_specialty_generics_stocks_are_covered_in_this_list\"><\/span><strong>Which branded pharma and specialty generics stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Dr. Reddy&#8217;s Laboratories at Rs 1,229.5 and Alkem Laboratories at Rs 4,947. Their return on equity ranges from 11.1% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 14.3%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_branded_pharma_and_specialty_generics_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do branded pharma and specialty generics stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Branded pharma and specialty generics stocks have a strong roadmap in India because rising healthcare access, a growing chronic disease burden and a trusted export base keep lifting demand for medicines. The main drivers are as follows. Chronic therapies. Long-term treatments give repeat demand. Export generics. Overseas approvals widen markets. Domestic brands. Doctors prescribe trusted medicines. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_JB_Chemicals_and_Pharmaceuticals_performed_financially\"><\/span><strong>How has JB Chemicals and Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P\/E of 54.6, above the industry P\/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Dr_Reddys_Laboratories_performed_financially\"><\/span><strong>How has Dr. Reddy&#8217;s Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P\/E of 32.6, below the industry P\/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Alkem_Laboratories_performed_financially\"><\/span><strong>How has Alkem Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P\/E of 27.1, below the industry P\/E of 36.0. Looking ahead, alkem&#8217;s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_branded_pharma_and_specialty_generics_stocks\"><\/span><strong>What risks should investors check before buying branded pharma and specialty generics stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying branded pharma and specialty generics stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_branded_pharma_and_specialty_generics_stocks_investment_advice\"><\/span><strong>Is this list of branded pharma and specialty generics stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are branded pharma and specialty generics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Branded pharma and specialty generics stocks are listed drug makers that sell branded medicines in India and generics abroad. Their earnings depend on new launches, chronic therapy growth, regulatory approvals and pricing. This list looks at three of them, JB Chemicals and Pharmaceuticals, Dr. Reddy's Laboratories and Alkem Laboratories, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which branded pharma and specialty generics stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers JB Chemicals and Pharmaceuticals, Dr. Reddy's Laboratories and Alkem Laboratories. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Dr. Reddy's Laboratories at Rs 1,229.5 and Alkem Laboratories at Rs 4,947. Their return on equity ranges from 11.1% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 14.3%.\"}},{\"@type\":\"Question\",\"name\":\"Why do branded pharma and specialty generics stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Branded pharma and specialty generics stocks have a strong roadmap in India because rising healthcare access, a growing chronic disease burden and a trusted export base keep lifting demand for medicines. The main drivers are as follows. Chronic therapies. Long-term treatments give repeat demand. Export generics. Overseas approvals widen markets. Domestic brands. Doctors prescribe trusted medicines. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has JB Chemicals and Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P\/E of 54.6, above the industry P\/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Dr. Reddy's Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P\/E of 32.6, below the industry P\/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.\"}},{\"@type\":\"Question\",\"name\":\"How has Alkem Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P\/E of 27.1, below the industry P\/E of 36.0. Looking ahead, alkem's strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying branded pharma and specialty generics stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying branded pharma and specialty generics stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of branded pharma and specialty generics stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Branded Pharma and Specialty Generics Stocks with a strong future roadmap: JB Chemicals and Pharmaceuticals, Dr. Reddy&#8217;s Laboratories and Alkem Laboratories. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.<\/p>\n","protected":false},"author":28,"featured_media":326325,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[10617,3803,15836,15838,7377,14176,15837],"class_list":["post-326326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-alkem-laboratories","tag-best-stocks","tag-branded-pharma-and-specialty-generics-stocks","tag-domestic-formulations-stocks","tag-dr-reddys-laboratories","tag-jb-chemicals-and-pharmaceuticals","tag-medicine-maker-business-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["326325"],"rank_math_title":["Branded Pharma and Specialty Generics Stocks"],"rank_math_description":["Compare 3 branded pharma and specialty generics stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 23 Oct 2026."],"rank_math_focus_keyword":["branded pharma and specialty generics stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-specialty-pharma-maker-global-generics-leader-and-branded-medicines-company.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=326326"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326326\/revisions"}],"predecessor-version":[{"id":326327,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326326\/revisions\/326327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/326325"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=326326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=326326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=326326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}